- Report
- April 2025
- 200 Pages
Global
From €4096EUR$4,490USD£3,501GBP
- Report
- May 2024
- 134 Pages
Global
From €5929EUR$6,499USD£5,067GBP
- Report
- August 2022
- 140 Pages
Global
From €3877EUR$4,250USD£3,314GBP
- Report
- March 2024
- 159 Pages
Global
From €7252EUR$7,950USD£6,199GBP
- Report
- April 2025
- 50 Pages
Global
From €2417EUR$2,650USD£2,066GBP
- Report
- April 2025
- 50 Pages
Global
From €2417EUR$2,650USD£2,066GBP
Dipyridamole is a drug used in the treatment of cardiovascular diseases. It is an antiplatelet agent, meaning it helps to prevent the formation of blood clots. It is used to reduce the risk of stroke in patients with atrial fibrillation, and to prevent blood clots in patients who have had a heart attack or who have had a stent placed in their coronary artery. It is also used to reduce the risk of recurrent stroke in patients who have had a transient ischemic attack (TIA). Dipyridamole is available in both oral and intravenous forms.
The dipyridamole market is a part of the larger cardiovascular drugs market. It is a growing market, driven by the increasing prevalence of cardiovascular diseases and the need for effective treatments. The market is expected to continue to grow in the coming years, as new treatments are developed and the demand for existing treatments increases.
Some of the companies in the dipyridamole market include Pfizer, Sanofi, Merck, Novartis, and Bayer. Show Less Read more